A new study reveals that a novel antimicrobial compound, part of a potential new class of antibiotics called GmPcides, has shown promise in treating flesh-eating bacterial infections in mice. These antibiotics target gram-positive bacteria, known for causing severe infections such as drug-resistant staph infections and toxic shock syndrome.
Researchers found that GmPcides, derived from ring-fused-2-pyridone molecules, significantly improved the health of mice infected with Streptococcus pyrogenes, reducing weight loss, ulcer size, and infection severity.
The compound appears to damage bacterial cell membranes, weakening their ability to spread and cause harm. GmPcides also seem less likely to promote drug resistance.
However, further research and human trials are needed before these antibiotics can be used in medical settings. The study was published on August 2 in ‘Science Advances’.
Peoplesmind
